# Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

> **NCT05114421** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- High Grade Fallopian Tube Serous Adenocarcinoma
- High Grade Ovarian Serous Adenocarcinoma
- Peritoneal High Grade Serous Adenocarcinoma
- Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
- Recurrent High Grade Ovarian Serous Adenocarcinoma
- Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma

## Interventions

- **DRUG:** Lenvatinib
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05114421
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-09
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05114421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05114421, "Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT05114421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*